ASC37_Dosage, benefits & legal status
Also known as ASC37o, ASC37i, ASC-37
A 41-amino-acid GLP-1, GIP and glucagon peptide with no human data of any kind, and company press releases as its entire evidence base.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is ASC37?
Plain language first. The technical label stays, but it never stands alone.Overview
It is the sibling of ASC36, the amylin peptide already on this site, and the triple-receptor answer to retatrutide. Everything published about it comes from company releases: weight loss in obese mice, pharmacokinetics in monkeys, and a claim that the injected depot lasts about 17 days in monkeys. No human has received it and no trial is registered. The company said in January 2026 that a phase 1 study would start in the second half of the year; by late October it was still saying it expected to file for permission to begin.
ASC37 is a peptide agonist at the GLP-1, GIP and glucagon receptors from Ascletis Pharma, the same three targets as retatrutide. The company said in July 2026 that it was engineered to have 41 alpha amino acids, enough to make it a biologic rather than a small molecule, and is developing it both as an oral tablet using its own absorption technology and as a subcutaneous depot selected in January 2026. Its sequence, structure and receptor potency values have not been disclosed.
What it's used for
Nothing yet. It is a preclinical obesity drug candidate in two formulations, a weekly tablet and a monthly injection. It is not in trials, not approved and not sold.
How does ASC37 work?
What it does in the body, and where.Three receptors, one peptide. GLP-1 and GIP both cut appetite and help insulin work; glucagon pushes the liver to release fuel and raises energy expenditure. Retatrutide is the furthest-developed drug built this way, and ASC37 is aimed at the same combination.
- 01Why the third receptor is the hard oneGlucagon raises blood sugar on its own, so a triple agonist has to balance it against the two receptors that lower it. Getting that balance wrong is why several triple agonists have stalled. Ascletis has not published its receptor potency numbers, so the balance it chose cannot be checked.
- 02Two delivery problems, two formulationsA 41-residue peptide is normally digested if swallowed and cleared within days if injected. The company's answer is an absorption technology for the tablet, reporting 3.5 to 7.9% of an oral dose reaching the blood in monkeys, and what it calls a self-assembly lipid depot for the injection, releasing the peptide slowly from under the skin.
- 03What a depot half-life measuresThe reported 17-day average half-life in monkeys describes how slowly the depot releases the peptide, not how long the molecule itself survives. The comparison drawn against retatrutide in its standard liquid formulation is between a depot and a non-depot, so it does not isolate the molecule.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Obese mice
Research only- Animal studyOver 11 days of once-daily injections, mice on 1 nanomole per kilogram lost 14.1% of body weight against 7.5% on the same dose of tirzepatide, reported at p = 0.0279.
- Animal studyHigher doses lost 30.1% at 10 nanomoles per kilogram and 41.5% at 30, both reported at p below 0.0001.
- No dataThe mice were injected once a day. The product is pitched as a once-monthly injection, so the dosing in the study does not match the dosing being proposed.
- No dataOnly the lowest ASC37 dose was matched to the tirzepatide dose. The two larger figures compare unequal doses.
Monkeys, and the two formulations
Research only- Animal studyOral bioavailability in monkeys was reported as 4.2% on average in 2025 and as a range of 3.5 to 7.9% in 2026.
- Animal studyThe oral half-life was reported as about 56 hours in 2025 and up to 79 hours in 2026. Inside the combination tablet with ASC36 it is given as up to 96 hours.
- Animal studyThe subcutaneous depot showed an average half-life of about 17 days, reported as 7-fold longer than retatrutide in January 2026 and against an absolute 2.5 days for retatrutide in July. The company says this confirms once-monthly dosing.
- No dataNo weight-loss data have been published for either formulation in monkeys, only pharmacokinetics.
In people
Research only- No dataNothing. No human has received ASC37 in any formulation, and no trial is registered anywhere.
- RegulatoryThe expected date for filing with the FDA has moved from the second quarter of 2026 to the third quarter and then to the last quarter, across four releases. The phase 1 study that January 2026 put in the second half of the year has not started.
The figures quoted as ASC37 beating tirzepatide by 88%, 301% and 453% are relative differences between mouse weight-loss percentages, and only the 88% compares matched doses. The mice were injected once daily while the product is pitched as monthly. The 17-day half-life is the depot gel's release rate measured against retatrutide in plain solution, not a property of the molecule. The o and i suffixes have never been defined in a release; the descriptions imply oral and injectable formulations of one peptide rather than two molecules. ASC37 is also not the ASC36 and ASC35 combination, and it is separate from ASC30, ASC35, ASC36, ASC39 and ASC47.
The published record
Papers and trials about ASC37
2 papers tagged human · 2 not reviews or lab · 0 clinical trial publications
Furthest stage reached: No clinical trial on record
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about ASC37
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Not measured in people
How much, and do you cycle it?
The range, and whether you take breaks.No human dose exists, intended once weekly by mouth, or once monthly by injection. No established pattern No range
Intended as a weekly tablet or a monthly injection. Neither has been given to a person, so there is no schedule to follow.
How long does it stay in the body?
The half-life, and where the figure comes from.Not measured in peopleNo figure
In monkeys the tablet showed an average of about 56 hours in 2025 and up to 79 hours in 2026, and the depot injection about 17 days. Depot figures mostly reflect how fast the depot releases the peptide. Nothing has been measured in a person.
Source: Ascletis press releases, monkey data only
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
ASC37 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Any human use: there is no trial, no dose and no product
- Anything sold under this name: the sequence has never been published, so a vial cannot be checked against a reference structure
Stop and get help
- Not applicable. No product exists and no trial is open
Common effects
- No human data have been published
- Approved drugs in this class cause nausea, vomiting and diarrhea most often; that has not been measured for ASC37
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is ASC37 approved?
And where the numbers on this page come from.No. ASC37 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteBy mouth (tablet) or under the skin (monthly depot); neither tested in people
- Checked23 October 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesAscletis selects ASC37 for clinical development, November 30, 2025Ascletis selects a once-monthly subcutaneous ASC37, January 20, 2026Ascletis reports mouse weight loss for subcutaneous ASC37, July 27, 2026Ascletis preclinical update on its oral peptide pipeline, October 19, 2026Ascletis publications page
What has happened recently
Not approved anywhere, and not yet in human testing. Ascletis (HKEX: 1672) named ASC37 as its first oral triple agonist candidate on November 30, 2025 and selected a once-monthly subcutaneous depot version on January 20, 2026, expecting to file with the FDA in the second quarter of 2026 and to start a phase 1 study in the second half of that year. The July 27, 2026 release moved the filing for both formulations to the third quarter, and the October 19, 2026 release moved the application for ASC37o and for the ASC36 and ASC37 combination to the last quarter of 2026. No filing has been confirmed as accepted, no trial is registered anywhere, there is no FDA substance record and no INN.
You can compare this against the whole library, or read how to check a seller.
What else is like ASC37?
Others in GLP-1 agonists, side by side.If you're weighing ASC37, it's worth reading Beinaglutide, Berobenatide, and BI 3034701 in the same class.
A 41-amino-acid GLP-1, GIP and glucagon peptide with no human data of any kind, and company press releases as its entire evidence base.
- Dose
- No human dose exists
- How often
- Intended once weekly by mouth, or once monthly by injection
China's own GLP-1, and the only one with a fully human sequence.
- Dose
- Set by the Chinese label
- How often
- Three times daily, before meals
An experimental GLP-1 shot built to be given monthly, now in Pfizer's phase 3 program.
- Dose
- 0.4 up to 2.4 mg weekly, or 3.2 to 4.8 mg monthly (trial doses)
- How often
- Weekly, then monthly in some trials
The drug that shows 'triple agonist' is a shape, not a mechanism.
- Dose
- No human dose disclosed; six dose groups are being tested
- How often
- Not disclosed
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Ascletis selects ASC37 for clinical development, November 30, 2025(2025)Monkey oral bioavailability averaged 4.2%, with an average observed half-life of about 56 hours. Reports in-vitro potency about 5-fold, 4-fold and 4-fold that of retatrutide at the three receptors. FDA application then expected in the second quarter of 2026.
- Ascletis selects a once-monthly subcutaneous ASC37, January 20, 2026(2026)Reports an average observed half-life of approximately 17 days for the subcutaneous depot formulations in monkeys, 7-fold longer than retatrutide, with in-vitro potency about 5-, 4- and 4-fold that of retatrutide. No weight-loss or human data. FDA application then expected in the second quarter of 2026, with a phase 1 study expected to begin in the second half of 2026.
- Ascletis reports mouse weight loss for subcutaneous ASC37, July 27, 2026(2026)Obese mice over 11 days of once-daily injections: tirzepatide at 1 nmol/kg lost 7.5% of body weight, ASC37 at the same dose 14.1% (p = 0.0279), at 10 nmol/kg 30.1% and at 30 nmol/kg 41.5%. States ASC37 was engineered to have 41 alpha amino acids, and reports a monkey depot half-life of about 17 days against 2.5 days for retatrutide.
- Ascletis preclinical update on its oral peptide pipeline, October 19, 2026(2026)Describes ASC37o as a once-weekly oral triple agonist with a monkey half-life up to 79 hours and oral bioavailability of 3.5 to 7.9%, FDA application expected in the last quarter of 2026. ASC37i appears only in the boilerplate with no data. The release does not define the o and i suffixes.
- Ascletis publications page(2026)Lists ASC37 as a GLP-1R/GIPR/GCGR triple agonist peptide in oral tablet form, citing a June 2026 ADA poster with the 4.2% monkey oral bioavailability. The page does not mention a subcutaneous ASC37.
Beyond these, 3 records are indexed. Browse the records